Insider Selling: Privia Health Group, Inc. (NASDAQ:PRVA) CEO Sells 5,985 Shares of Stock

Privia Health Group, Inc. (NASDAQ:PRVAGet Rating) CEO Matthew Shawn Morris sold 5,985 shares of the stock in a transaction on Wednesday, September 21st. The shares were sold at an average price of $37.30, for a total transaction of $223,240.50. Following the completion of the sale, the chief executive officer now directly owns 121,739 shares of the company’s stock, valued at $4,540,864.70. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Matthew Shawn Morris also recently made the following trade(s):

  • On Thursday, August 25th, Matthew Shawn Morris sold 68,102 shares of Privia Health Group stock. The shares were sold at an average price of $42.20, for a total transaction of $2,873,904.40.
  • On Wednesday, July 20th, Matthew Shawn Morris sold 120,589 shares of Privia Health Group stock. The shares were sold at an average price of $34.08, for a total transaction of $4,109,673.12.
  • On Thursday, July 7th, Matthew Shawn Morris sold 68,912 shares of Privia Health Group stock. The shares were sold at an average price of $33.24, for a total transaction of $2,290,634.88.

Privia Health Group Stock Performance

PRVA traded down $0.25 during midday trading on Friday, hitting $34.41. The company had a trading volume of 1,115,504 shares, compared to its average volume of 822,928. The company has a market capitalization of $3.83 billion, a PE ratio of -74.80 and a beta of 1.06. Privia Health Group, Inc. has a twelve month low of $17.99 and a twelve month high of $44.64. The firm’s 50-day simple moving average is $38.19 and its 200-day simple moving average is $30.24.

Privia Health Group (NASDAQ:PRVAGet Rating) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.08). The company had revenue of $335.54 million during the quarter, compared to analyst estimates of $312.04 million. Privia Health Group had a negative net margin of 4.17% and a negative return on equity of 9.44%. As a group, sell-side analysts anticipate that Privia Health Group, Inc. will post -0.26 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on PRVA shares. Canaccord Genuity Group increased their price objective on shares of Privia Health Group from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, August 25th. Cowen increased their price objective on shares of Privia Health Group from $35.00 to $44.00 and gave the company an “outperform” rating in a research note on Friday, August 12th. SVB Leerink increased their price objective on shares of Privia Health Group from $33.00 to $46.00 and gave the company an “outperform” rating in a research note on Friday, August 12th. BTIG Research increased their target price on shares of Privia Health Group to $45.00 in a research report on Monday, August 15th. Finally, Credit Suisse Group increased their target price on shares of Privia Health Group from $33.00 to $41.00 and gave the stock an “outperform” rating in a research report on Friday, August 12th. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Privia Health Group presently has a consensus rating of “Buy” and an average price target of $44.58.

Institutional Investors Weigh In On Privia Health Group

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Privia Health Group by 16.2% in the 1st quarter. Vanguard Group Inc. now owns 4,255,881 shares of the company’s stock valued at $113,759,000 after acquiring an additional 593,178 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Privia Health Group by 34.1% in the 1st quarter. Bank of New York Mellon Corp now owns 4,138,080 shares of the company’s stock valued at $110,611,000 after purchasing an additional 1,052,856 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Privia Health Group by 71.8% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 2,780,204 shares of the company’s stock valued at $80,960,000 after purchasing an additional 1,162,270 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Privia Health Group by 108.4% in the 1st quarter. BlackRock Inc. now owns 2,579,166 shares of the company’s stock valued at $68,940,000 after purchasing an additional 1,341,730 shares during the last quarter. Finally, Riverbridge Partners LLC boosted its stake in shares of Privia Health Group by 1.5% in the 2nd quarter. Riverbridge Partners LLC now owns 2,080,967 shares of the company’s stock valued at $60,598,000 after purchasing an additional 31,010 shares during the last quarter. Institutional investors and hedge funds own 62.81% of the company’s stock.

About Privia Health Group

(Get Rating)

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.

Featured Articles

Insider Buying and Selling by Quarter for Privia Health Group (NASDAQ:PRVA)

Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.